Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Icotinib in EGFR-mutated NSCLC
NCT02960607Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02960607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960607.